Mereo BioPharma Group plc Quarterly Income Tax Expense (Benefit) in USD from Q1 2023 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Mereo BioPharma Group plc quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2023 to Q2 2024.
  • Mereo BioPharma Group plc Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $0.000.
  • Mereo BioPharma Group plc annual Income Tax Expense (Benefit) for 2023 was -$532K, a 25.9% increase from 2022.
Income Tax Expense (Benefit), Quarterly (USD)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $0 $0 Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 $0 $0 Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q2 2023 $0 Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 $0 Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.